PRENTKI RONALD J 4
4 · PROGENICS PHARMACEUTICALS INC · Filed Feb 7, 2005
Insider Transaction Report
Form 4
PRENTKI RONALD J
DirectorPresident
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2005-02-07−8,000→ 48,800 totalExercise: $9.25Exp: 2008-10-07→ Common Stock (8,000 underlying) - Sale
Common Stock (par value $0.0013)
2005-02-04$21.15/sh−6,000$126,900→ 39,578 total - Exercise/Conversion
Common Stock (par value $0.0013)
2005-02-04$9.25/sh+18,000$166,500→ 51,578 total - Exercise/Conversion
Common Stock (par value $0.0013)
2005-02-07$9.25/sh+8,000$74,000→ 41,578 total - Sale
Common Stock (par value $0.0013)
2005-02-04$21.00/sh−4,000$84,000→ 47,578 total - Sale
Common Stock (par value $0.0013)
2005-02-04$21.12/sh−2,000$42,240→ 45,578 total - Sale
Common Stock (par value $0.0013)
2005-02-07$21.00/sh−8,000$168,000→ 33,578 total - Exercise/Conversion
Stock Option (Right to Buy)
2005-02-04−18,000→ 56,800 totalExercise: $9.25Exp: 2008-10-07→ Common Stock (18,000 underlying)
Footnotes (2)
- [F1]On October 8, 1998, the Reporting Person received from the Issuer, pursuant to the Issuer's 1996 Stock Option Plan, options to acquire 190,000 shares of Common Stock of the Issuer. The stock options became exercisable in equal installments over 5 years on each October 7th, with the last option becoming exercisable on October 7, 2003. The Reporting Person previously exercised 115,200 options under this grant. The Reporting Person is exercising additional options under this grant in pre-established increments under and in accordance with the provisions of a previously established Plan of Sale under Rule 10b5-1, which was established in accordance with the policies and procedures of the Issuer approved by its Board of Directors.
- [F2]Includes 15,800 shares of restricted stock granted on July 1, 2004, which become unrestricted in four equal annual installments beginning on June 20, 2005.